Form 4 for OGN Organon & Co.
Accepted 2024-04-03 00:00:00 ET · period of report 2024-03-31 · accession 0001821825-24-000044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-04-03 | 2024-03-31 | OGN | Weaver Kirke | Gen. Counsel, Corp. Secy | M - OptEx | $0.00 | +13.6K | 22.8K | +148% | $0 |
| DM | 2024-04-03 | 2024-03-31 | OGN | Weaver Kirke | Gen. Counsel, Corp. Secy | F - Tax | $18.80 | -3,882 | 28.3K | -12% | -$73.0K |
| DM | 2024-04-03 | 2024-03-31 | OGN | Weaver Kirke | Gen. Counsel, Corp. Secy | M - OptEx | $0.00 | -13.6K | 4,294 | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-31 | M | A | 6,200 | $0.00 | 27,801 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-31 | F | D | 1,767 | $18.80 | 26,034 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-31 | M | A | 3,125 | $0.00 | 29,159 | D | — | — | |
| 4 | Common | Common Stock | 2024-03-31 | M | A | 4,294 | $0.00 | 22,825 | D | — | — | |
| 5 | Common | Common Stock | 2024-03-31 | F | D | 1,224 | $18.80 | 21,601 | D | — | — | |
| 6 | Common | Common Stock | 2024-03-31 | F | D | 891 | $18.80 | 28,268 | D | — | — | |
| 7 | Derivative | Restricted Stock Units | 2024-03-31 | M | D | 6,200 | $0.00 | 12,400 | D | — · — to — | 6,200 Common Stock | (F1) Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. (F4) The Reporting Person was granted RSUs on March 31, 2023. On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. |
| 8 | Derivative | Restricted Stock Units | 2024-03-31 | M | D | 3,125 | $0.00 | 3,125 | D | — · — to — | 3,125 Common Stock | (F1) Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. (F3) The Reporting Person was granted RSUs on November 7, 2022, which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. (F2) The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. |
| 9 | Derivative | Restricted Stock Units | 2024-03-31 | M | D | 4,294 | $0.00 | 4,294 | D | — · — to — | 4,294 Common Stock | (F1) Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. (F2) The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. |